GlassScriptPhysician profile
Chad M Lahman
NPI 1235791757
$1,367.19
in general payments reported to CMS, 2019-2025
13 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.08 · 2023: $15.15 · 2024: $156 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $786 · Food and Beverage: $529 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $785.80 |
| Food and Beverage | $529.31 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $856.97 | 2025 | Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Pfizer INC. | $97.45 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.41 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $65.80 | 2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $56.95 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $45.36 | 2024-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $36.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.20 | 2024-2025 | |
| Haemonetics Corporation | $23.47 | 2025 | Teg6s Hemostasis System |
| Lexicon Pharmaceuticals, INC. | $20.58 | 2024 | |
| Atricure, INC. | $20.42 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $18.50 | 2025 | Repatha |
| Lilly USA, LLC | $16.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Lahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.